SG11202012161RA - Oligonucleotides for modulating scn9a expression - Google Patents
Oligonucleotides for modulating scn9a expressionInfo
- Publication number
- SG11202012161RA SG11202012161RA SG11202012161RA SG11202012161RA SG11202012161RA SG 11202012161R A SG11202012161R A SG 11202012161RA SG 11202012161R A SG11202012161R A SG 11202012161RA SG 11202012161R A SG11202012161R A SG 11202012161RA SG 11202012161R A SG11202012161R A SG 11202012161RA
- Authority
- SG
- Singapore
- Prior art keywords
- oligonucleotides
- modulating
- scn9a expression
- scn9a
- expression
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18179339 | 2018-06-22 | ||
EP18194982 | 2018-09-18 | ||
PCT/EP2019/066223 WO2019243430A1 (en) | 2018-06-22 | 2019-06-19 | Oligonucleotides for modulating scn9a expression |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202012161RA true SG11202012161RA (en) | 2021-01-28 |
Family
ID=66867163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202012161RA SG11202012161RA (en) | 2018-06-22 | 2019-06-19 | Oligonucleotides for modulating scn9a expression |
Country Status (16)
Country | Link |
---|---|
US (1) | US12116576B2 (en) |
EP (1) | EP3810776A1 (en) |
JP (2) | JP2021527437A (en) |
KR (1) | KR20210027384A (en) |
CN (1) | CN112513273A (en) |
AU (1) | AU2019291050A1 (en) |
BR (1) | BR112020026169A2 (en) |
CA (1) | CA3103756A1 (en) |
CL (1) | CL2020003304A1 (en) |
CR (1) | CR20200626A (en) |
IL (1) | IL279024A (en) |
MX (1) | MX2020013930A (en) |
PE (1) | PE20210314A1 (en) |
SG (1) | SG11202012161RA (en) |
WO (1) | WO2019243430A1 (en) |
ZA (1) | ZA202007542B (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102422625B1 (en) | 2015-10-09 | 2022-07-20 | 유니버시티 오브 사우스앰톤 | Regulation of gene expression and screening of deregulated protein expression |
ES2882500T3 (en) | 2015-12-14 | 2021-12-02 | Cold Spring Harbor Laboratory | Antisense oligomers for the treatment of Dravet syndrome |
AU2018322319B2 (en) | 2017-08-25 | 2021-08-05 | Stoke Therapeutics, Inc. | Antisense oligomers for treatment of conditions and diseases |
CA3099280A1 (en) | 2018-05-04 | 2019-11-07 | Stoke Therapeutics, Inc. | Methods and compositions for treatment of cholesteryl ester storage disease |
AR120817A1 (en) * | 2019-12-20 | 2022-03-23 | Hoffmann La Roche | ENHANCED OLIGONUCLEOTIDES TO INHIBIT SCN9A EXPRESSION |
IL298063A (en) | 2020-05-11 | 2023-01-01 | Stoke Therapeutics Inc | opa1 antisense oligomers for the treatment of conditions and diseases |
WO2022061108A2 (en) * | 2020-09-17 | 2022-03-24 | Q-State Biosciences, Inc. | Therapeutic compositions for treating pain via multiple targets |
WO2022147541A1 (en) * | 2021-01-04 | 2022-07-07 | Exicure Operating Company | Compounds for modulating scn9a expression |
WO2022232395A2 (en) * | 2021-04-28 | 2022-11-03 | Q-State Biosciences, Inc. | Therapeutic compositions for treating pain via multiple targets |
WO2024002045A1 (en) * | 2022-06-27 | 2024-01-04 | Aoan Biosciences | Oligonucleotide delivery agents, pharmaceutical compositions and methods using the same |
WO2024169770A1 (en) * | 2023-02-17 | 2024-08-22 | 苏州时安生物技术有限公司 | Sirna inhibiting scn9a gene expression, pharmaceutical composition and use thereof |
WO2024244000A1 (en) * | 2023-06-02 | 2024-12-05 | 宜明(麻省)细胞生物科技有限公司 | Engineered sgrna design and preparation method |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6573067B1 (en) * | 1998-01-29 | 2003-06-03 | Yale University | Nucleic acid encoding sodium channels in dorsal root ganglia |
WO2002081628A2 (en) * | 2001-04-05 | 2002-10-17 | Ribozyme Pharmaceuticals, Incorporated | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies |
GB0021617D0 (en) * | 2000-09-02 | 2000-10-18 | Imp College Innovations Ltd | Diagnosis and treatment of cancer |
EP2341148A3 (en) | 2001-04-12 | 2012-05-30 | Imperial Innovations Limited | Diagnosis and treatment of cancer |
US20050080031A1 (en) * | 2001-05-18 | 2005-04-14 | Sirna Therapeutics, Inc. | Nucleic acid treatment of diseases or conditions related to levels of Ras, HER2 and HIV |
US7659082B2 (en) | 2002-02-19 | 2010-02-09 | Xenon Pharmaceuticals Inc. | Methods for identifying analgesic agents |
US8090542B2 (en) | 2002-11-14 | 2012-01-03 | Dharmacon Inc. | Functional and hyperfunctional siRNA |
AU2006311725B2 (en) | 2005-11-04 | 2011-11-24 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of NAV1.8 gene |
WO2009033027A2 (en) | 2007-09-05 | 2009-03-12 | Medtronic, Inc. | Suppression of scn9a gene expression and/or function for the treatment of pain |
KR20110087436A (en) | 2010-01-26 | 2011-08-03 | 주식회사 씨티아이바이오 | Antisense Oligonucleotides of Potential Sodium Ion Channel Subtype 9 (SSC 9A) |
HUE054179T2 (en) * | 2010-06-23 | 2021-08-30 | Curna Inc | Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna |
WO2012162732A1 (en) | 2011-06-02 | 2012-12-06 | The University Of Queensland | Assays for sodium ion channel modulators and uses thereof |
EA201591754A1 (en) | 2013-03-14 | 2016-01-29 | Ридженерон Фармасьютикалз, Инк. | HUMAN ANTIBODIES TO NA1.7 |
JP2017001991A (en) * | 2015-06-11 | 2017-01-05 | 大日本住友製薬株式会社 | Novel benzoxazolone compound |
EP3786297A1 (en) | 2016-03-14 | 2021-03-03 | F. Hoffmann-La Roche AG | Oligonucleotides for reduction of pd-l1 expression |
CA3029141A1 (en) * | 2016-07-06 | 2018-01-11 | Crispr Therapeutics Ag | Materials and methods for treatment of pain related disorders |
IL315358A (en) * | 2016-08-18 | 2024-11-01 | Univ California | Crispr-cas genome engineering via a modular aav delivery system |
RU2748834C2 (en) | 2016-09-16 | 2021-05-31 | Олипасс Корпорейшн | Antisense oligonucleotides against scn9a |
JP2021511027A (en) | 2018-01-12 | 2021-05-06 | ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブRoche Innovation Center Copenhagen A/S | Alpha-synuclein antisense oligonucleotide and its use |
EP3740573A1 (en) | 2018-01-18 | 2020-11-25 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting srebp1 |
JP7379387B2 (en) | 2018-06-05 | 2023-11-14 | エフ. ホフマン-ラ ロシュ アーゲー | Oligonucleotides for controlling ATXN2 expression |
AU2019294414B2 (en) | 2018-06-29 | 2023-06-29 | F. Hoffmann-La Roche Ag | Compounds |
WO2021008637A2 (en) | 2020-10-12 | 2021-01-21 | 深圳顺络电子股份有限公司 | Stacked shielded inductor |
-
2019
- 2019-06-19 SG SG11202012161RA patent/SG11202012161RA/en unknown
- 2019-06-19 MX MX2020013930A patent/MX2020013930A/en unknown
- 2019-06-19 CR CR20200626A patent/CR20200626A/en unknown
- 2019-06-19 EP EP19730816.6A patent/EP3810776A1/en active Pending
- 2019-06-19 PE PE2020002100A patent/PE20210314A1/en unknown
- 2019-06-19 JP JP2020571417A patent/JP2021527437A/en active Pending
- 2019-06-19 BR BR112020026169-6A patent/BR112020026169A2/en not_active Application Discontinuation
- 2019-06-19 AU AU2019291050A patent/AU2019291050A1/en not_active Abandoned
- 2019-06-19 WO PCT/EP2019/066223 patent/WO2019243430A1/en active Application Filing
- 2019-06-19 CA CA3103756A patent/CA3103756A1/en active Pending
- 2019-06-19 CN CN201980050900.8A patent/CN112513273A/en active Pending
- 2019-06-19 KR KR1020217002056A patent/KR20210027384A/en not_active Withdrawn
-
2020
- 2020-11-26 IL IL279024A patent/IL279024A/en unknown
- 2020-12-03 ZA ZA2020/07542A patent/ZA202007542B/en unknown
- 2020-12-18 CL CL2020003304A patent/CL2020003304A1/en unknown
- 2020-12-22 US US17/130,451 patent/US12116576B2/en active Active
-
2024
- 2024-02-09 JP JP2024018384A patent/JP2024056820A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3810776A1 (en) | 2021-04-28 |
US12116576B2 (en) | 2024-10-15 |
CR20200626A (en) | 2021-02-22 |
ZA202007542B (en) | 2022-06-29 |
CL2020003304A1 (en) | 2021-06-04 |
JP2021527437A (en) | 2021-10-14 |
KR20210027384A (en) | 2021-03-10 |
JP2024056820A (en) | 2024-04-23 |
IL279024A (en) | 2021-01-31 |
US20210238608A1 (en) | 2021-08-05 |
WO2019243430A1 (en) | 2019-12-26 |
CN112513273A (en) | 2021-03-16 |
MX2020013930A (en) | 2021-03-09 |
CA3103756A1 (en) | 2019-12-26 |
AU2019291050A1 (en) | 2020-12-24 |
BR112020026169A2 (en) | 2021-04-06 |
PE20210314A1 (en) | 2021-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202007542B (en) | Oligonucleotides for modulating scn9a expression | |
GB201904709D0 (en) | Chemically modified oligonucleotides | |
SG11201911704UA (en) | Antisense oligonucleotides for modulating the function of a t cell | |
EP3236976A4 (en) | Rna interference agents for p21 gene modulation | |
ZA201808291B (en) | Antisense oligonucleotides for modulating htra1 expression | |
RS64073B1 (en) | Tmem16a modulators | |
IL279056A (en) | Oligonucleotides for modulating tau expression | |
SG10201910373PA (en) | Cryptographic datashare control for blockchain | |
IL276357A (en) | Oligonucleotides for modulating tmem106b expression | |
GB2596231B (en) | Modulators | |
IL271039A (en) | Antisense oligonucleotides for modulating htra1 expression | |
IL279929A (en) | Oligonucleotides for modulating rtel1 expression | |
GB2585803B (en) | Electro-absorption modulator | |
GB202112727D0 (en) | Application for letters patent | |
EP3268009A4 (en) | Methods for modulating bone density | |
GB2585587B (en) | Modulators | |
GB201805865D0 (en) | Genes | |
GB201713019D0 (en) | Methods for controlling deposits | |
IL282731A (en) | Organosulfur compounds | |
GB201608907D0 (en) | Means for modulating gene expression | |
GB201714330D0 (en) | Oligonucleotides | |
GB201918992D0 (en) | GPR52 modulator compounds | |
GB201918974D0 (en) | Gpr52 modulator compounds | |
GB201916298D0 (en) | GPR52 modulator compounds | |
GB2582110B (en) | User selected control features for powertrain management |